FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283540> ?p ?o ?g. }

• W4379283540 endingPage "3098" @default.
• W4379283540 startingPage "3098" @default.
• W4379283540 abstract "3098 Background: ABM-1310 is a novel small-molecule BRAF inhibitor with high water solubility, cell permeability, and blood-brain barrier penetration as demonstrated in preclinical studies. Here we report preliminary findings from a first-in-patient phase 1 study of ABM-1310. Methods: This US multicenter, open-label, dose-escalation with cohort expansion trial includes adult pts with advanced BRAFv600-mutated solid tumors, including those with active brain metastasis from solid tumors or primary malignant brain tumors. Previous BRAF/MEK inhibitor treatment is permitted. In dose escalation Part A, ABM-1310 monotherapy is given orally twice a day (25–250 mg bid). In dose escalation Part B, ABM-1310 (100 and 200 mg bid) is given in combination with the MEK inhibitor cobimetinib (60 mg QD d1–21 q4w). Primary objectives: determine maximum tolerated dose and recommended phase 2 dose of ABM-1310 ± cobimetinib. Secondary objectives: safety/tolerability; pharmacokinetics; preliminary efficacy. Dose-limiting toxicities (DLTs) are assessed during cycle 1 by a 3+3 design. Results: As of November 28, 2022, 20 pts (65% male; median age 57.5 years) have been treated with ABM-1310 monotherapy across six dose levels in Part A: 25 mg bid (n=3); 50 mg bid (n=3); 100 mg bid (n=4); 150 mg bid (n=4); 200 mg bid (n=4); 250 mg bid (n=2). All pts experienced adverse events (AEs), most frequently skin rash (40%) and QT prolongation (20%). Three pts had drug-related grade ≥3 AEs (nausea/vomiting, QT prolongation and rash) and two had drug-related serious AEs (SAEs) (nausea/vomiting and creatinine increase). Among 16 efficacy evaluable pts, two (pleomorphic xanthoastrocytoma and glioblastoma) had a partial response (PR) and eight had stable disease (SD) as their best response (per RECIST or RANO). In Part B, two ABM-1310 dose levels were assessed in combination with cobimetinib: 100 mg bid (n=3) and 200 mg bid (n=3). Four pts had AEs and drug-related AEs (rash and QT prolongation). There were no SAEs. Among three evaluable pts, one (melanoma) had a PR and one had SD as their best response. There were no confirmed DLTs in either dose-escalation Part A or B, although a few pts had ABM-1310 treatment interruption and subsequent dose reduction. No pts discontinued prematurely for any safety or tolerability reason and there were no drug-related deaths. Preliminary assessment of ABM-1310 drug exposure vs dosage showed a linear dose-proportional relationship. This trial is ongoing. Conclusions: ABM-1310 at the currently tested doses up to 200 mg bid, either alone or in combination with cobimetinib, was generally well tolerated, with no new safety signals. Preliminary efficacy data demonstrate favorable activity of ABM-1310 in pts with BRAFv600-mutated solid tumors, including primary CNS tumors, and pts previously refractory to other BRAF/MEK inhibitors and I/O therapies. Clinical trial information: NCT04190628 ." @default.
• W4379283540 created "2023-06-05" @default.
• W4379283540 creator A5009078484 @default.
• W4379283540 creator A5017967471 @default.
• W4379283540 creator A5025685342 @default.
• W4379283540 creator A5026538331 @default.
• W4379283540 creator A5059499380 @default.
• W4379283540 creator A5062065609 @default.
• W4379283540 creator A5063253432 @default.
• W4379283540 creator A5072495193 @default.
• W4379283540 creator A5088042471 @default.
• W4379283540 creator A5088715559 @default.
• W4379283540 date "2023-06-01" @default.
• W4379283540 modified "2023-09-27" @default.
• W4379283540 title "A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with <i>BRAFv600</i>-mutated solid tumors." @default.
• W4379283540 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.3098" @default.
• W4379283540 hasPublicationYear "2023" @default.
• W4379283540 type Work @default.
• W4379283540 citedByCount "0" @default.
• W4379283540 crossrefType "journal-article" @default.
• W4379283540 hasAuthorship W4379283540A5009078484 @default.
• W4379283540 hasAuthorship W4379283540A5017967471 @default.
• W4379283540 hasAuthorship W4379283540A5025685342 @default.
• W4379283540 hasAuthorship W4379283540A5026538331 @default.
• W4379283540 hasAuthorship W4379283540A5059499380 @default.
• W4379283540 hasAuthorship W4379283540A5062065609 @default.
• W4379283540 hasAuthorship W4379283540A5063253432 @default.
• W4379283540 hasAuthorship W4379283540A5072495193 @default.
• W4379283540 hasAuthorship W4379283540A5088042471 @default.
• W4379283540 hasAuthorship W4379283540A5088715559 @default.
• W4379283540 hasConcept C112705442 @default.
• W4379283540 hasConcept C126322002 @default.
• W4379283540 hasConcept C143998085 @default.
• W4379283540 hasConcept C197934379 @default.
• W4379283540 hasConcept C2778375690 @default.
• W4379283540 hasConcept C2778570526 @default.
• W4379283540 hasConcept C2780580376 @default.
• W4379283540 hasConcept C2780852908 @default.
• W4379283540 hasConcept C71924100 @default.
• W4379283540 hasConcept C90924648 @default.
• W4379283540 hasConcept C98274493 @default.
• W4379283540 hasConceptScore W4379283540C112705442 @default.
• W4379283540 hasConceptScore W4379283540C126322002 @default.
• W4379283540 hasConceptScore W4379283540C143998085 @default.
• W4379283540 hasConceptScore W4379283540C197934379 @default.
• W4379283540 hasConceptScore W4379283540C2778375690 @default.
• W4379283540 hasConceptScore W4379283540C2778570526 @default.
• W4379283540 hasConceptScore W4379283540C2780580376 @default.
• W4379283540 hasConceptScore W4379283540C2780852908 @default.
• W4379283540 hasConceptScore W4379283540C71924100 @default.
• W4379283540 hasConceptScore W4379283540C90924648 @default.
• W4379283540 hasConceptScore W4379283540C98274493 @default.
• W4379283540 hasIssue "16_suppl" @default.
• W4379283540 hasLocation W43792835401 @default.
• W4379283540 hasOpenAccess W4379283540 @default.
• W4379283540 hasPrimaryLocation W43792835401 @default.
• W4379283540 hasRelatedWork W2070411187 @default.
• W4379283540 hasRelatedWork W2074207917 @default.
• W4379283540 hasRelatedWork W2074629895 @default.
• W4379283540 hasRelatedWork W2156337883 @default.
• W4379283540 hasRelatedWork W2371615325 @default.
• W4379283540 hasRelatedWork W2372442000 @default.
• W4379283540 hasRelatedWork W2378568667 @default.
• W4379283540 hasRelatedWork W2394317912 @default.
• W4379283540 hasRelatedWork W2888625382 @default.
• W4379283540 hasRelatedWork W2964872415 @default.
• W4379283540 hasVolume "41" @default.
• W4379283540 isParatext "false" @default.
• W4379283540 isRetracted "false" @default.
• W4379283540 workType "article" @default.